HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 5 (May)

1. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
   J Infect Dis, 195(11): 1694-704. [Abstract] [Full-text]
2. Spirituality as a component of holistic self-care practices in human immunodeficiency virus-positive women with histories of abuse.
   Holist Nurs Pract, 21(3): 105-12; quiz 113-4. [Abstract] [Full-text]
3. Associative and predictive biomarkers of dementia in HIV-1-infected patients.
   Neurology, 68(18): 1481-7. [Abstract] [Full-text]
4. The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy.
   FASEB J, 21(7): 1367-75. [Abstract] [Full-text]
5. A longitudinal study of the prevalence, development, and persistence of HIV/sexually transmitted infection risk behaviors in delinquent youth: implications for health care in the community.
   Pediatrics, 119(5): e1126-41. [Abstract] [Full-text]
6. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
   Expert Opin Pharmacother, 8(7): 957-64. [Abstract] [Full-text]
7. Access denied? The status of co-receptor inhibition to counter HIV entry.
   Expert Opin Pharmacother, 8(7): 923-33. [Abstract] [Full-text]
8. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.
   Pediatrics, 119(5): e1142-8. [Abstract] [Full-text]
9. hnRNP E1 and E2 have distinct roles in modulating HIV-1 gene expression.
   Retrovirology, 4: 28. [Abstract] [Full-text]
10. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Pediatrics, 119(5): e1116-20. [Abstract] [Full-text]
11. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.
    J Clin Microbiol, 45(5): 1659-62. [Abstract] [Full-text]
12. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene.
    J Clin Microbiol, 45(5): 1565-71. [Abstract] [Full-text]
13. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies.
    J Clin Microbiol, 45(5): 1572-80. [Abstract] [Full-text]
14. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells.
    Ann Neurol, 61(5): 466-75. [Abstract] [Full-text]
15. Bridging the gap between antiretroviral access and adherence in Mexico.
    Qual Health Res, 17(5): 599-611. [Abstract] [Full-text]
16. Factors leading to self-disclosure of a positive HIV diagnosis in Nairobi, Kenya: people living with HIV/AIDS in the Sub-Sahara.
    Qual Health Res, 17(5): 586-98. [Abstract] [Full-text]
17. TRAF activation of C/EBPbeta (NF-IL6) via p38 MAPK induces HIV-1 gene expression in monocytes/macrophages.
    Microbes Infect, 9(6): 721-8. [Abstract] [Full-text]
18. Vietnam: integrating palliative care into HIV/AIDS and cancer care.
    J Pain Symptom Manage, 33(5): 578-83. [Abstract] [Full-text]
19. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes.
    J Subst Abuse Treat, 32(4): 423-9. [Abstract] [Full-text]
20. Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.
    J Subst Abuse Treat, 32(4): 399-409. [Abstract] [Full-text]
21. Dysregulated energy expenditure in HIV-infected patients: a mechanistic review.
    Clin Infect Dis, 44(11): 1509-17. [Abstract] [Full-text]
22. Retention in care: a challenge to survival with HIV infection.
    Clin Infect Dis, 44(11): 1493-9. [Abstract] [Full-text]
23. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Clin Infect Dis, 44(11): 1484-92. [Abstract] [Full-text]
24. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Clin Infect Dis, 44(11): 1475-83. [Abstract] [Full-text]
25. Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals.
    Clin Infect Dis, 44(11): e96-9. [Abstract] [Full-text]
26. The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120.
    FEBS Lett, 581(10): 2060-4. [Abstract] [Full-text]
27. The silent defense: micro-RNA directed defense against HIV-1 replication.
    Retrovirology, 4: 26. [Abstract] [Full-text]
28. Optimization and characterization of tRNA-shRNA expression constructs.
    Nucleic Acids Res, 35(8): 2620-8. [Abstract] [Full-text]
29. HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms.
    Nucleic Acids Res, 35(8): 2695-704. [Abstract] [Full-text]
30. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.
    Infect Genet Evol, 7(3): 391-8. [Abstract] [Full-text]
31. Optimal drug treatment regimens for HIV depend on adherence.
    J Theor Biol, 246(3): 499-509. [Abstract] [Full-text]
32. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.
    Blood, 109(10): 4272-9. [Abstract] [Full-text]
33. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals.
    Blood, 109(10): 4296-305. [Abstract] [Full-text]
34. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
    Infect Genet Evol, 7(3): 382-90. [Abstract] [Full-text]
35. Predictors of discordant reports of sexual and HIV/sexually transmitted infection risk behaviors among heterosexual couples.
    Sex Transm Dis, 34(5): 302-8. [Abstract] [Full-text]
36. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004.
    Sex Transm Dis, 34(5): 288-93. [Abstract] [Full-text]
37. Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy.
    Antiviral Res, 75(2): 159-66. [Abstract] [Full-text]
38. Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity.
    Antiviral Res, 75(2): 93-103. [Abstract] [Full-text]
39. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
    Antiviral Res, 75(2): 129-38. [Abstract] [Full-text]
40. Dichotomous effects of C-C chemokines in HIV-1 pathogenesis.
    Immunol Lett, 110(1): 1-5. [Abstract] [Full-text]
41. When time is more than money: the allocation of time between work and leisure in HIV-infected patients.
    Soc Sci Med, 64(11): 2355-61. [Abstract] [Full-text]
42. Human immunodeficiency virus-like particles activate multiple types of immune cells.
    Virology, 362(2): 331-41. [Abstract] [Full-text]
43. Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naïve patients.
    Virology, 362(2): 294-303. [Abstract] [Full-text]
44. Isolation and characterization of mouse-human microcell hybrid cell clones permissive for infectious HIV particle release.
    Virology, 362(2): 283-93. [Abstract] [Full-text]
45. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.
    Retrovirology, 4: 29. [Abstract] [Full-text]
46. Prevalence and risk factors for HIV-1 infection in rural Kilimanjaro region of Tanzania: implications for prevention and treatment.
    BMC Public Health, 7: 58. [Abstract] [Full-text]
47. A model of HIV disclosure: disclosure and types of social relationships.
    J Am Acad Nurse Pract, 19(5): 242-50. [Abstract] [Full-text]
48. De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
    J Med Chem, 50(10): 2370-84. [Abstract] [Full-text]
49. Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor.
    J Med Chem, 50(10): 2285-8. [Abstract] [Full-text]
50. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
    J Med Chem, 50(10): 2301-9. [Abstract] [Full-text]
51. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.
    J Infect Dis, 195(12): 1774-8. [Abstract] [Full-text]
52. Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection.
    J Infect Dis, 195(12): 1765-73. [Abstract] [Full-text]
53. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
    J Infect Dis, 195(12): 1762-4. [Abstract] [Full-text]
54. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    J Infect Dis, 195(12): 1754-61. [Abstract] [Full-text]
55. 'When you have children, you're obliged to live': motherhood, chronic illness and biographical disruption.
    Sociol Health Illn, 29(4): 610-26. [Abstract] [Full-text]
56. Anesthesia in HIV-infected children.
    Paediatr Anaesth, 17(6): 509-19. [Abstract] [Full-text]
57. Multiple sclerosis-like clinical and magnetic resonance imaging findings in human immunodeficiency virus positive-case.
    Neurologist, 13(3): 154-7. [Abstract] [Full-text]
58. Fully-spliced HIV-1 RNAs are reverse transcribed with similar efficiencies as the genomic RNA in virions and cells, but more efficiently in AZT-treated cells.
    Retrovirology, 4: 30. [Abstract] [Full-text]
59. Understanding the isomerization of the HIV-1 dimerization initiation domain by the nucleocapsid protein.
    J Mol Biol, 369(3): 812-28. [Abstract] [Full-text]
60. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.
    J Mol Biol, 369(3): 696-709. [Abstract] [Full-text]
61. Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo.
    J Virol, 81(11): 6146-50. [Abstract] [Full-text]
62. Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway.
    J Virol, 81(11): 5864-71. [Abstract] [Full-text]
63. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells.
    J Virol, 81(11): 5872-81. [Abstract] [Full-text]
64. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1.
    J Virol, 81(11): 6043-56. [Abstract] [Full-text]
65. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes.
    J Virol, 81(11): 5919-28. [Abstract] [Full-text]
66. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point.
    J Virol, 81(11): 5759-65. [Abstract] [Full-text]
67. Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS.
    J Virol, 81(11): 5594-606. [Abstract] [Full-text]
68. SATB1-binding sequences and Alu-like motifs define a unique chromatin context in the vicinity of human immunodeficiency virus type 1 integration sites.
    J Virol, 81(11): 5617-27. [Abstract] [Full-text]
69. Development of a cell-based assay probing the specific interaction between the human immunodeficiency virus type 1 nucleocapsid and psi RNA in vivo.
    J Virol, 81(11): 6151-5. [Abstract] [Full-text]
70. Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1.
    J Virol, 81(11): 5547-60. [Abstract] [Full-text]
71. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.
    J Virol, 81(11): 5579-93. [Abstract] [Full-text]
72. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.
    J Virol, 81(11): 5658-68. [Abstract] [Full-text]
73. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection.
    J Virol, 81(11): 5460-71. [Abstract] [Full-text]
74. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV.
    J Gen Intern Med, 22(6): 822-5. [Abstract] [Full-text]
75. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans.
    J Gen Intern Med, 22(6): 749-54. [Abstract] [Full-text]
76. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.
    J Viral Hepat, 14(6): 392-5. [Abstract] [Full-text]
77. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    J Viral Hepat, 14(6): 387-91. [Abstract] [Full-text]
78. Therapeutic issues in HIV/HCV-coinfected patients.
    J Viral Hepat, 14(6): 371-86. [Abstract] [Full-text]
79. The use of caspofungin in HIV-infected individuals.
    Expert Opin Investig Drugs, 16(6): 899-908. [Abstract] [Full-text]
80. C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells.
    J Invest Dermatol, 127(6): 1436-43. [Abstract] [Full-text]
81. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
    Eur J Med Chem, 42(5): 567-79. [Abstract] [Full-text]
82. Defining and solving the essential protein-protein interactions in HIV infection.
    J Struct Biol, 158(2): 148-55. [Abstract] [Full-text]
83. Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection.
    Am J Med Sci, 333(5): 271-5. [Abstract] [Full-text]
84. Good outcome in HIV-infected refugees after resettlement in New Zealand: population study.
    Intern Med J, 37(5): 290-4. [Abstract] [Full-text]
85. Role of previous hospitalization in clinically-significant MRSA infection among HIV-infected inpatients: results of a case-control study.
    BMC Infect Dis, 7: 36. [Abstract] [Full-text]
86. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review.
    BMC Public Health, 7: 63. [Abstract] [Full-text]
87. Knowledge about safe motherhood and HIV/AIDS among school pupils in a rural area in Tanzania.
    BMC Pregnancy Childbirth, 7: 5. [Abstract] [Full-text]
88. Associations between sexual behaviour change in young people and decline in HIV prevalence in Zambia.
    BMC Public Health, 7: 60. [Abstract] [Full-text]
89. Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters.
    Gene Ther, 14(11): 872-82. [Abstract] [Full-text]
90. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
    BMC Infect Dis, 7: 37. [Abstract] [Full-text]
91. Rapid progression of carotid lesions in HAART-treated HIV-1 patients.
    Atherosclerosis, 192(2): 407-12. [Abstract] [Full-text]
92. Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: Implications for HIV-associated dementia.
    Free Radic Biol Med, 42(12): 1866-78. [Abstract] [Full-text]
93. An enhanced agent based model of the immune system response.
    Cell Immunol, 244(2): 77-9. [Abstract] [Full-text]
94. Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.
    J Biol Chem, 282(21): 15743-53. [Abstract] [Full-text]
95. Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study).
    J Infect, 54(6): 603-8. [Abstract] [Full-text]
96. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
    J Infect, 54(6): 609-16. [Abstract] [Full-text]
97. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.
    J Infect, 54(6): 597-602. [Abstract] [Full-text]
98. Efavirenz.
    Expert Opin Pharmacother, 8(8): 1137-45. [Abstract] [Full-text]
99. Managing multiple and extensively drug-resistant tuberculosis and HIV.
    Expert Opin Pharmacother, 8(8): 1035-7. [Abstract] [Full-text]
100. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects.
     Clin Infect Dis, 44(12): 1657-61. [Abstract] [Full-text]
101. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
     Clin Infect Dis, 44(12): 1647-56. [Abstract] [Full-text]
102. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans.
     Clin Infect Dis, 44(12): 1639-46. [Abstract] [Full-text]
103. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci.
     Clin Infect Dis, 44(12): 1632-8. [Abstract] [Full-text]
104. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study.
     Clin Infect Dis, 44(12): 1625-31. [Abstract] [Full-text]
105. Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man.
     Clin Infect Dis, 44(12): e121-3. [Abstract] [Full-text]
106. In their own voices: a qualitative study of women's risk for intimate partner violence and HIV in South Africa.
     Violence Against Women, 13(6): 583-602. [Abstract] [Full-text]
107. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
     Proc Natl Acad Sci U S A, 104(20): 8467-71. [Abstract] [Full-text]
108. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings.
     Am J Public Health, 97(6): 1034-40. [Abstract] [Full-text]
109. Managing Medicare's HIV caseload in the era of suppressive therapy.
     Am J Public Health, 97(6): 1053-9. [Abstract] [Full-text]
110. History of childhood sexual abuse and HIV risk behaviors in homosexual and bisexual men.
     Am J Public Health, 97(6): 1107-12. [Abstract] [Full-text]
111. Reproductive health of adolescent girls perinatally infected with HIV.
     Am J Public Health, 97(6): 1047-52. [Abstract] [Full-text]
112. Prevalence of HIV infection and predictors of high-transmission sexual risk behaviors among men who have sex with men.
     Am J Public Health, 97(6): 1067-75. [Abstract] [Full-text]
113. The effectiveness of state and national policy on the implementation of perinatal HIV prevention interventions.
     Am J Public Health, 97(6): 1041-6. [Abstract] [Full-text]
114. REAL men: a group-randomized trial of an HIV prevention intervention for adolescent boys.
     Am J Public Health, 97(6): 1084-9. [Abstract] [Full-text]
115. Tip of the Iceberg: young men who have sex with men, the Internet, and HIV risk.
     Am J Public Health, 97(6): 1113-7. [Abstract] [Full-text]
116. "He won't use condoms": HIV-infected women's struggles in primary relationships with serodiscordant partners.
     Am J Public Health, 97(6): 1015-22. [Abstract] [Full-text]
117. Bisexual Latino men and HIV and sexually transmitted infections risk: an exploratory analysis.
     Am J Public Health, 97(6): 1102-6. [Abstract] [Full-text]
118. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia.
     Am J Public Health, 97(6): 974-7. [Abstract] [Full-text]
119. Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States.
     Am J Public Health, 97(6): 1060-6. [Abstract] [Full-text]
120. The inevitability of infidelity: sexual reputation, social geographies, and marital HIV risk in rural Mexico.
     Am J Public Health, 97(6): 986-96. [Abstract] [Full-text]
121. Modern marriage, men's extramarital sex, and HIV risk in southeastern Nigeria.
     Am J Public Health, 97(6): 997-1005. [Abstract] [Full-text]
122. Male-to-female transgender and transsexual clients of HIV service programs in Los Angeles County, California.
     Am J Public Health, 97(6): 1030-3. [Abstract] [Full-text]
123. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis.
     Exp Neurol, 205(2): 506-12. [Abstract] [Full-text]
124. Acceptability of perinatal rapid point-of-care HIV testing in an area of low HIV prevalence in the UK.
     Arch Dis Child, 92(6): 505-8. [Abstract] [Full-text]
125. Computerized HIV preventive intervention for adolescents: indications of efficacy.
     Am J Public Health, 97(6): 1027-30. [Abstract] [Full-text]
126. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort.
     Contraception, 75(6): 461-7. [Abstract] [Full-text]
127. Demographic, clinical, and virologic characteristics of African-born persons with HIV/AIDS in a Minnesota hospital.
     AIDS Patient Care STDS, 21(5): 356-65. [Abstract] [Full-text]
128. Age difference in rates of mental health/substance abuse and behavioral care in HIV-positive adults.
     AIDS Patient Care STDS, 21(5): 347-55. [Abstract] [Full-text]
129. Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients.
     AIDS Patient Care STDS, 21(5): 329-38. [Abstract] [Full-text]
130. Gender differences in survival in an HIV/AIDS cohort from São Paulo, Brazil.
     AIDS Patient Care STDS, 21(5): 321-8. [Abstract] [Full-text]
131. A quantitative study on the condom-use behaviors of eighteen- to twenty-four-year-old urban African American males.
     AIDS Patient Care STDS, 21(5): 306-20. [Abstract] [Full-text]
132. Antiretroviral therapies associated with lipoatrophy in HIV-infected women.
     AIDS Patient Care STDS, 21(5): 297-305. [Abstract] [Full-text]
133. Bilateral leg swelling as the initial and predominant presentation of HIV and associated pulmonary arterial hypertension.
     AIDS Patient Care STDS, 21(5): 293-6. [Abstract] [Full-text]
134. Treatment outcomes of patients with HIV and tuberculosis.
     Am J Respir Crit Care Med, 175(11): 1199-206. [Abstract] [Full-text]
135. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
     Lancet Infect Dis, 7(6): 402-9. [Abstract] [Full-text]
136. HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages.
     Blood, 109(11): 4832-8. [Abstract] [Full-text]
137. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.
     Blood, 109(11): 4671-8. [Abstract] [Full-text]
138. Time trends in failure to return for HIV test results.
     Sex Transm Dis, 34(6): 397-400. [Abstract] [Full-text]
139. Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men.
     Sex Transm Dis, 34(6): 401-7. [Abstract] [Full-text]
140. The efficacy of behavioral interventions in reducing HIV risk sex behaviors and incident sexually transmitted disease in black and Hispanic sexually transmitted disease clinic patients in the United States: a meta-analytic review.
     Sex Transm Dis, 34(6): 319-32. [Abstract] [Full-text]
141. An assessment of sites where persons go to meet sexual partners in St. James, Jamaica, using the PLACE method.
     Sex Transm Dis, 34(6): 410-5. [Abstract] [Full-text]
142. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients.
     Sex Transm Dis, 34(6): 367-70. [Abstract] [Full-text]
143. Protease inhibitor-based regimens for HIV therapy: safety and efficacy.
     J Acquir Immune Defic Syndr, 45: S5-13; quiz S28-31. [Abstract] [Full-text]
144. Metabolic issues associated with protease inhibitors.
     J Acquir Immune Defic Syndr, 45: S19-26. [Abstract] [Full-text]
145. The role of adherence to antiretroviral therapy in the management of HIV infection.
     J Acquir Immune Defic Syndr, 45: S14-8. [Abstract] [Full-text]
146. HIV-associated nephropathy in the era of antiretroviral therapy.
     Am J Med, 120(6): 488-92. [Abstract] [Full-text]
147. An exploratory investigation of dietary intake and weight in human immunodeficiency virus-seropositive individuals in Accra, Ghana.
     J Am Diet Assoc, 107(6): 1008-13. [Abstract] [Full-text]
148. Assessing dietary intake of drug-abusing Hispanic adults with and without human immunodeficiency virus infection.
     J Am Diet Assoc, 107(6): 968-76. [Abstract] [Full-text]
149. Renal and gastrointestinal amyloidosis in an HIV-infected injection drug user.
     Int J STD AIDS, 18(5): 357-8. [Abstract] [Full-text]
150. HIV-infected children vaccination coverage and safety in a Western European cohort: a retrospective study.
     Int J STD AIDS, 18(5): 351-3. [Abstract] [Full-text]
151. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
     Int J STD AIDS, 18(5): 343-6. [Abstract] [Full-text]
152. Sexually transmitted disease symptom management behaviours among female sex workers in Tashkent, Uzbekistan.
     Int J STD AIDS, 18(5): 324-8. [Abstract] [Full-text]
153. Cytomegalovirus viral load testing of blood using quantitative polymerase chain reaction in acutely unwell HIV-1-positive patients lacks diagnostic utility.
     Int J STD AIDS, 18(5): 321-3. [Abstract] [Full-text]
154. Correlates of late HIV diagnosis: implications for testing policy.
     Int J STD AIDS, 18(5): 312-7. [Abstract] [Full-text]
155. Patterns of in vitro lymphoproliferative responses among HTLV-1-infected subjects: upregulation by HTLV-1 during HIV-1 co-infection.
     Scand J Immunol, 65(6): 577-80. [Abstract] [Full-text]
156. Biochip array-based analysis of plasma cytokines in HIV patients with immunological and virological discordance.
     Scand J Immunol, 65(6): 549-54. [Abstract] [Full-text]
157. Coping with HIV treatment side effects: conceptualization, measurement, and linkages.
     AIDS Behav, 11(4): 575-85. [Abstract] [Full-text]
158. Assessing representativeness of sampling methods for reaching men who have sex with men: a direct comparison of results obtained from convenience and probability samples.
     AIDS Behav, 11(4): 596-602. [Abstract] [Full-text]
159. A dimeric lactone from Ardisia japonica with inhibitory activity for HIV-1 and HIV-2 ribonuclease H.
     J Nat Prod, 70(5): 839-41. [Abstract] [Full-text]
160. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
     Virology, 363(2): 447-53. [Abstract] [Full-text]
161. A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry.
     Virology, 363(2): 310-8. [Abstract] [Full-text]
162. Molecular determinants of HIV-1 intersubtype recombination potential.
     Virology, 363(2): 437-46. [Abstract] [Full-text]
163. Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications.
     Virology, 363(2): 462-72. [Abstract] [Full-text]
164. Diversity of HIV-1 RNA and DNA in breast milk from HIV-1-infected mothers.
     Virology, 363(2): 256-60. [Abstract] [Full-text]
165. A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG.
     Virology, 363(2): 261-71. [Abstract] [Full-text]
166. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
     Virology, 363(2): 280-7. [Abstract] [Full-text]
167. Prevalence and correlates of sexual behaviors among karen villagers in northern Thailand.
     AIDS Behav, 11(4): 611-8. [Abstract] [Full-text]
168. Conducting Internet-based HIV/STD prevention survey research: considerations in design and evaluation.
     AIDS Behav, 11(4): 505-21. [Abstract] [Full-text]
169. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV.
     AIDS Behav, 11(4): 603-10. [Abstract] [Full-text]
170. Perceptions of a community sample about participation in future HIV vaccine trials in south India.
     AIDS Behav, 11(4): 619-27. [Abstract] [Full-text]
171. Global Fund grant programmes: an analysis of evaluation scores.
     Lancet, 369(9575): 1807-13. [Abstract] [Full-text]
172. Patient and staff perspectives on the use of a computer counseling tool for HIV and sexually transmitted infection risk reduction.
     J Adolesc Health, 40(6): 572.e9-16. [Abstract] [Full-text]
173. Break the silence: HIV/AIDS knowledge, attitudes, and educational needs among Arab university students in United Arab Emirates.
     J Adolesc Health, 40(6): 572.e1-8. [Abstract] [Full-text]
174. Challenges in replicating interventions.
     J Adolesc Health, 40(6): 514-20. [Abstract] [Full-text]
175. Partnership selection and formation: a case study of developing adolescent health community-researcher partnerships in fifteen U.S. communities.
     J Adolesc Health, 40(6): 489-98. [Abstract] [Full-text]
176. Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda.
     AIDS Res Hum Retroviruses, 23(5): 755-60. [Abstract] [Full-text]
177. Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine.
     AIDS Res Hum Retroviruses, 23(5): 748-54. [Abstract] [Full-text]
178. Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy.
     AIDS Res Hum Retroviruses, 23(5): 741-7. [Abstract] [Full-text]
179. Cell-free infectivity of HIV type 1 produced in nonpermissive cells is only moderately impacted by C-terminal Env truncation despite abrogation of viral spread.
     AIDS Res Hum Retroviruses, 23(5): 729-40. [Abstract] [Full-text]
180. RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs.
     AIDS Res Hum Retroviruses, 23(5): 713-9. [Abstract] [Full-text]
181. Helicobacter pylori infection in symptomatic HIV-seropositive and -seronegative patients: a case-control study.
     AIDS Res Hum Retroviruses, 23(5): 709-12. [Abstract] [Full-text]
182. Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs.
     AIDS Res Hum Retroviruses, 23(5): 699-708. [Abstract] [Full-text]
183. Increased mortality in rural patients with HIV in New England.
     AIDS Res Hum Retroviruses, 23(5): 693-8. [Abstract] [Full-text]
184. The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection.
     AIDS Res Hum Retroviruses, 23(5): 686-92. [Abstract] [Full-text]
185. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
     AIDS Res Hum Retroviruses, 23(5): 682-5. [Abstract] [Full-text]
186. Introduction of HIV type 1 into an isolated population: molecular epidemiologic study from Greenland.
     AIDS Res Hum Retroviruses, 23(5): 675-81. [Abstract] [Full-text]
187. Identification and characterization of HIV type 1 subtypes present in the Kingdom of Saudi Arabia: high level of genetic diversity found.
     AIDS Res Hum Retroviruses, 23(5): 667-74. [Abstract] [Full-text]
188. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
     Ther Drug Monit, 29(3): 361-7. [Abstract] [Full-text]
189. Palatial erosion caused by Mycobacterium Avium complex in a human immunodeficiency virus infected child.
     Pediatr Infect Dis J, 26(6): 546-8. [Abstract] [Full-text]
190. Child mortality according to maternal and infant HIV status in Zimbabwe.
     Pediatr Infect Dis J, 26(6): 519-26. [Abstract] [Full-text]
191. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
     J Acquir Immune Defic Syndr, 45(2): 193-200. [Abstract] [Full-text]
192. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.
     J Acquir Immune Defic Syndr, 45(2): 168-73. [Abstract] [Full-text]
193. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women.
     J Acquir Immune Defic Syndr, 45(2): 161-7. [Abstract] [Full-text]
194. HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
     PLoS Comput Biol, 3(5): e87. [Abstract] [Full-text]
195. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.
     PLoS Pathog, 3(5): e63. [Abstract] [Full-text]
196. Synthesis and anti-HIV-1 activity of new MKC-442 analogues with an alkynyl-substituted 6-benzyl group.
     Arch Pharm (Weinheim), 340(5): 225-35. [Abstract] [Full-text]
197. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
     J Clin Virol, 39(2): 125-31. [Abstract] [Full-text]
198. Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.
     Eur J Pharmacol, 565(1): 54-9. [Abstract] [Full-text]
199. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
     J Acquir Immune Defic Syndr, 45(2): 206-9. [Abstract] [Full-text]
200. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.
     J Acquir Immune Defic Syndr, 45(2): 218-23. [Abstract] [Full-text]
201. Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.
     J Clin Virol, 39(2): 82-6. [Abstract] [Full-text]
202. Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1.
     J Virol, 81(12): 6643-51. [Abstract] [Full-text]
203. Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site.
     J Virol, 81(12): 6614-22. [Abstract] [Full-text]
204. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.
     J Virol, 81(12): 6563-72. [Abstract] [Full-text]
205. The host protein Staufen1 participates in human immunodeficiency virus type 1 assembly in live cells by influencing pr55Gag multimerization.
     J Virol, 81(12): 6216-30. [Abstract] [Full-text]
206. Probability sample estimates of bathhouse sexual risk behavior.
     J Acquir Immune Defic Syndr, 45(2): 231-8. [Abstract] [Full-text]
207. HIV prevalence and undiagnosed infection among a community sample of gay men in Scotland.
     J Acquir Immune Defic Syndr, 45(2): 224-30. [Abstract] [Full-text]
208. High prevalence of subtherapeutic plasma concentrations of efavirenz in children.
     J Acquir Immune Defic Syndr, 45(2): 133-6. [Abstract] [Full-text]
209. FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells.
     J Biol Chem, 282(22): 15973-80. [Abstract] [Full-text]
210. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
     J Acquir Immune Defic Syndr, 45(2): 183-92. [Abstract] [Full-text]
211. The changing pattern of hospital care for persons living with HIV: 2000 through 2004.
     J Acquir Immune Defic Syndr, 45(2): 239-46. [Abstract] [Full-text]
212. Clinically significant anemia in HIV-infected pregnant women in India is not a major barrier to zidovudine use for prevention of maternal-to-child transmission.
     J Acquir Immune Defic Syndr, 45(2): 210-7. [Abstract] [Full-text]
213. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
     J Virol, 81(12): 6187-96. [Abstract] [Full-text]
214. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
     J Virol, 81(12): 6548-62. [Abstract] [Full-text]
215. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.
     J Virol, 81(12): 6742-51. [Abstract] [Full-text]
216. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
     J Virol, 81(12): 6402-11. [Abstract] [Full-text]
217. Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain.
     J Virol, 81(12): 6434-45. [Abstract] [Full-text]
218. Selective and nonselective packaging of cellular RNAs in retrovirus particles.
     J Virol, 81(12): 6623-31. [Abstract] [Full-text]
219. The effect of acids on the survival of HIV during drug injection.
     J Acquir Immune Defic Syndr, 45(2): 144-50. [Abstract] [Full-text]
220. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
     J Acquir Immune Defic Syndr, 45(2): 174-82. [Abstract] [Full-text]
221. Identification of 3 phylogenetically related HIV-1 BG intersubtype circulating recombinant forms in Cuba.
     J Acquir Immune Defic Syndr, 45(2): 151-60. [Abstract] [Full-text]
222. Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects.
     J Acquir Immune Defic Syndr, 45(2): 137-43. [Abstract] [Full-text]
223. Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpesvirus therapy and long-term outcome.
     J Med Virol, 79(7): 931-4. [Abstract] [Full-text]
224. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
     J Med Virol, 79(7): 880-6. [Abstract] [Full-text]
225. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
     J Med Virol, 79(7): 865-72. [Abstract] [Full-text]
226. Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
     J Med Virol, 79(7): 873-9. [Abstract] [Full-text]
227. Estimating the rate of accumulating drug resistance mutations in the HIV genome.
     Value Health, 10(3): 204-13. [Abstract] [Full-text]
228. Probing Na(+)-induced changes in the HIV-1 TAR conformational dynamics using NMR residual dipolar couplings: new insights into the role of counterions and electrostatic interactions in adaptive recognition.
     Biochemistry, 46(22): 6525-35. [Abstract] [Full-text]
229. High throughput functional analysis of HIV-1 env genes without cloning.
     J Virol Methods, 143(1): 104-11. [Abstract] [Full-text]
230. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays?
     J Virol Methods, 143(1): 86-94. [Abstract] [Full-text]
231. Quantitative multiplex assay for simultaneous detection of the Indiana serotype of vesicular stomatitis virus and HIV gag.
     J Virol Methods, 143(1): 55-64. [Abstract] [Full-text]
232. Comparison of pp65 antigenemia, quantitative PCR and DNA hybrid capture for detection of cytomegalovirus in transplant recipients and AIDS patients.
     J Virol Methods, 143(1): 23-8. [Abstract] [Full-text]
233. Impact of HIV and AIDS on surgical practice.
     Ann R Coll Surg Engl, 89(4): 354-8. [Abstract] [Full-text]
234. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites.
     PLoS Med, 4(5): e181. [Abstract] [Full-text]
235. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells.
     Hum Gene Ther, 18(5): 413-22. [Abstract] [Full-text]
236. Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection.
     BMC Neurosci, 8: 31. [Abstract] [Full-text]
237. Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma.
     J Clin Oncol, 25(16): 2230-5. [Abstract] [Full-text]
238. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape.
     J Infect Dis, 196(1): 50-5. [Abstract] [Full-text]
239. Glucocorticoid-induced tumor necrosis factor receptor family-related protein triggering enhances HIV-specific CD4+ T cell cytokine secretion and protects HIV-specific CD4+ T cells from apoptosis.
     J Infect Dis, 196(1): 43-9. [Abstract] [Full-text]
240. CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant malawian women with plasmodium falciparum malaria and HIV-1 infection.
     J Infect Dis, 196(1): 38-42. [Abstract] [Full-text]
241. HIV, malaria, and infant anemia as risk factors for postneonatal infant mortality among HIV-seropositive women in Kisumu, Kenya.
     J Infect Dis, 196(1): 30-7. [Abstract] [Full-text]
242. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection.
     J Infect Dis, 196(1): 23-9. [Abstract] [Full-text]
243. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
     J Infect Dis, 196(1): 15-22. [Abstract] [Full-text]
244. Late postnatal transmission of HIV-1 and associated factors.
     J Infect Dis, 196(1): 10-4. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.